• The Lancet Gastroenterology & Hepatology in conversation with

  • By: The Lancet Group
  • Podcast

The Lancet Gastroenterology & Hepatology in conversation with

By: The Lancet Group
  • Summary

  • Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.

    © 2024 The Lancet Group
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
    Nov 1 2024

    Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

    Read the full articles:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00233-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    34 mins
  • Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
    Jul 31 2024

    Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    18 mins
  • Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy
    Jul 1 2024

    Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00084-0?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Show more Show less
    25 mins

What listeners say about The Lancet Gastroenterology & Hepatology in conversation with

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.